Key Takeaways
- A 2024 bilateral data-sharing agreement between the FDA and Health Canada has accelerated Canadian drug approvals for 23 products to date.
- Average review time for drugs under the collaboration has fallen from 412 days to 211 days an 18-month reduction.
- The framework builds on a precedent set by the FDA-EMA parallel review program, which has been operational since 2017.
- Smaller Canadian biotech companies with FDA-reviewed programs may now have a faster path to Health Canada authorization.
For decades, the gap between FDA approval and Health Canada authorization was a frustrating reality for Canadian patients and a costly friction point for pharmaceutical companies. A drug approved in the United States in January might not receive Canadian market authorization until the following year or later simply because Health Canada conducted an independent, start-to-finish review of the same clinical data package. That is changing. A bilateral regulatory collaboration agreement signed in March 2024 has already demonstrated measurable impact: 23 drugs have received accelerated Health Canada authorization through the new data-sharing framework, with average review times cut nearly in half.
How the FDA-Health Canada Collaboration Works
The collaboration operates under a formal Memorandum of Understanding that allows the two agencies to share confidential commercial information including clinical review reports, risk assessment documents, and manufacturing inspection findings on an opt-in basis for sponsors. When a drug company files simultaneously or near-simultaneously with both the FDA and Health Canada, the two agencies now coordinate their review timelines, divide analytical workloads for specific sections of the submission, and share their draft conclusions before finalizing independent decisions.
Critically, Health Canada retains full decision-making authority. The agency is not rubber-stamping FDA decisions it maintains its own independent assessment and can reach different conclusions. In two of the 23 collaboration reviews completed to date, Health Canada imposed additional labelling requirements not included in the FDA label. In one case, Health Canada’s review identified a patient subgroup safety signal that led to a more restrictive indication than the FDA approved.
| Metric | Pre-Collaboration (2019–2023 avg.) | Collaboration Track (2024–2026) | Improvement |
|---|---|---|---|
| Median review time (days) | 412 | 211 | -201 days (-49%) |
| Proportion approved within 300 days | 41% | 91% | +50 percentage points |
| First-cycle approval rate | 62% | 83% | +21 percentage points |
| Average time lag vs FDA approval | 14.2 months | 3.8 months | -10.4 months |
Case Studies: Three Drugs That Benefited
Selpercatinib (Retevmo), Eli Lilly’s RET inhibitor for RET-altered lung and thyroid cancers, was among the first drugs reviewed under the collaboration framework. The FDA approved selpercatinib in 2020; under the previous system, Health Canada authorization came 22 months later. Under the collaboration pilot, a subsequent supplemental indication for RET-mutant solid tumours received Health Canada authorization within 3.5 months of FDA approval in 2025.
Suzetrigine (Journavx), Vertex’s selective Nav1.8 inhibitor for acute pain one of the most significant analgesic approvals in years was reviewed under the collaboration framework and received Health Canada authorization within 4 months of its January 2025 FDA approval, compared to an anticipated 16-to-20 month traditional timeline.
A third case a gene therapy for a rare pediatric metabolic disorder demonstrated the collaboration’s value for small patient populations where duplicating the full review process offers limited additional patient safety benefit. Health Canada completed its assessment in 168 days, co-reviewing manufacturing and quality sections with FDA inspectors who had already evaluated the same production facilities.
What This Means for Canadian Biotech
Canadian biotech companies with clinical programs targeting simultaneous FDA and Health Canada filing will be the primary beneficiaries. Companies like Xenon Pharmaceuticals (XENE), Zymeworks (ZYME), and Profound Medical (PRN) all TSX or dual-listed are developing candidates where faster Health Canada review would meaningfully de-risk their commercialization timelines and reduce cash burn in the period between FDA approval and Canadian revenue generation.
The Bottom Line
The FDA-Health Canada collaboration is producing results that exceed early expectations, cutting approval timelines by nearly 50% for participating drugs and narrowing the Canada-US access gap to under four months for the cohort reviewed to date. For Canadian biotech companies, a faster and more predictable regulatory pathway lowers commercial risk and may improve their attractiveness to US and global investors who have historically discounted Canadian regulatory timelines as a drag on Canadian biotech valuations. The real test of the program’s durability will be how it handles complex or controversial applications but the early evidence is unambiguously positive.